NASDAQ:SBFM
Sunshine Biopharma Inc.
Sunshine Biopharma Inc.'s revenue grew 4.1% in fiscal 2025 to $36.3M while operating margin fell to −17.2%. Free cash flow was −$5.5M, −15.2% of revenue.Summary generated from Sunshine Biopharma Inc.'s SEC filings. Latest annual report filed Apr 3, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$36.3M
Revenue growth+4.1%
Revenue, 5-yr CAGR+247.7%
Gross margin33.8%
Operating margin−17.2%
Net margin−16.5%
ROICn/a
Return on equity−25.7%
Debt / equityn/a
Free cash flow−$5.5M
FCF margin−15.2%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 4 | 24 | 35 | 36 |
| Operating income | −2 | −27 | −5 | −6 | −6 |
| Net income | −12 | −27 | −5 | −5 | −6 |
| Free cash flow | −2 | −5 | −9 | −14 | −6 |
Recent filings
- 8-KEntry into a material agreement
Oct 9, 2026 - S-1Registration statement
Oct 2, 2026 - 8-KResults of a shareholder vote
Sep 16, 2026 - 8-KOther events
Sep 11, 2026 - S-1Registration statement
Aug 28, 2026 - 8-KDirector or officer change
Aug 28, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 4Insider transaction report
Aug 11, 2026